Trial
NCT03044353
Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
GlaxoSmithKline
Collaborators
—
Condition
Amyloidosis
Intervention
GSK2315698 (CPHPC)
Why stopped
Change in benefit/risk profile
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-10-16